Join to View Full Profile
2200 Webster St#511San Francisco, CA 94115
Dr. Minor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1976 - 1978
Sutter Health/California Pacific Medical CenterResidency, Internal Medicine, 1974 - 1976
University of California San Francisco School of MedicineClass of 1974
Certifications & Licensure
CA State Medical License 1975 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Clinical Trial of Sutent to Treat Metastatic Melanoma Start of enrollment: 2007 Sep 01
- Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma Start of enrollment: 2010 Dec 01
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
- Join now to see all
Publications & Presentations
PubMed
- Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas.David R Minor, Kevin B Kim, R Krishna M Karuturi, Mohammed Kashani-Sabet
Frontiers in Oncology. 2023-01-01 - 8 citationsA Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.David R Minor, Kevin B Kim, Ricky T Tong, Max C Wu, Mohammed Kashani-Sabet
Cancer Biotherapy & Radiopharmaceuticals. 2022-02-01 - 14 citationsImmune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.Ahmad A. Tarhini, Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen
Journal for Immunotherapy of Cancer. 2021-05-01
Press Mentions
Promising New Drug Could Help Patients Battling Deadly and Difficult to Treat Form of MelanomaMarch 8th, 2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
